Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $11.80.

A number of analysts have issued reports on CMPX shares. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. D. Boral Capital reissued a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds have recently modified their holdings of the stock. Rovin Capital UT ADV purchased a new stake in shares of Compass Therapeutics during the 3rd quarter valued at about $25,000. Intech Investment Management LLC purchased a new stake in Compass Therapeutics during the 3rd quarter worth approximately $30,000. XTX Topco Ltd purchased a new stake in Compass Therapeutics during the 3rd quarter worth approximately $37,000. SG Americas Securities LLC increased its holdings in Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after purchasing an additional 5,515 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Compass Therapeutics during the 2nd quarter worth approximately $41,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Stock Up 20.2 %

CMPX opened at $3.10 on Friday. The firm has a market cap of $426.53 million, a P/E ratio of -8.38 and a beta of 0.92. Compass Therapeutics has a 52 week low of $0.76 and a 52 week high of $3.13. The business’s fifty day simple moving average is $1.70 and its 200 day simple moving average is $1.55.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. As a group, equities analysts expect that Compass Therapeutics will post -0.35 EPS for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.